Inhibrx Biosciences Earnings Call Transcripts
Fiscal Year 2026
-
Interim phase II data show INBRX-106 plus pembrolizumab achieved a 44% ORR versus 21.4% for pembrolizumab alone in first-line PD-L1-positive head and neck cancer, with deeper and more complete responses and a manageable safety profile. Robust T cell activation supports further phase III development.
-
Ozekibart plus FOLFIRI showed a 20% ORR and 5.5-month median PFS in late-line CRC, with durable responses and a favorable safety profile. Plans are underway for first-line registrational trials and expansion into earlier lines and other tumor types.
Fiscal Year 2025
-
Ozekibart showed significant efficacy in chondrosarcoma, doubling PFS and reducing risk of progression or death by 52%. Promising response rates were also seen in late-line colorectal cancer and Ewing sarcoma, with a combined market potential exceeding $2.5 billion.